Northwire Canada EditionSunday, July 12, 2026
Sign inSubscribe
Northwire
⌕
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%

Healthcare

Page 15
  1. May 22, 2026 · 07:30 · BCT · Routine +

    ASCO Data Confirms Survival Benefit Amidst Dilution Headwinds

    BriaCell Presentations Highlight Positive Clinical Data for Bria-IMT(TM) at ASCO 2026

    01
  2. May 22, 2026 · 07:00 · MDNA · Material −

    Medicenna Files $13M Financing at Deep Discount as Cash Dwindles and Stock Spirals

    Medicenna Announces the Filing of its Prospectus Supplement and Investment Term Sheet

    02
  3. May 22, 2026 · 06:50 · ARCH · Routine +

    Arch Biopartners Doses First Patient in Phase II AKI Trial Amidst Dilution Concerns

    Arch Biopartners announces Royal Columbian Hospital has dosed its first patient in its Phase II cardiac surgery-associated AKI trial

    03
  4. May 22, 2026 · 06:31 · CHS · Routine +

    Comprehensive Healthcare Confirms Debt Settlement Amidst SaaS Growth Push

    Comprehensive Healthcare Announces Participation in the IFEBP Conference and Confirms Previously Announced Shares for Debt Settlement

    04
  5. May 21, 2026 · 20:15 · NXG · Routine +

    NexgenRx Sustains Growth Trajectory with Q1 Profitability; AI Initiative Signals Digital Push

    NexgenRx Announces Solid Q1 2026 Results with Continued Increasing Revenue, Net Income and EBITDA Growth

    05
  6. May 21, 2026 · 18:01 · FRX · Routine +

    Fennec Pharmaceuticals Clinical Data Supports Adult Expansion Amidst Strong Q1 Revenue Growth

    Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK(TM) at the 2026 ASCO Annual Meeting

    06
  7. May 21, 2026 · 17:00 · MPH · Routine +

    Medicure Inc.

    Medicure Reports Financial Results for Quarter Ended March 31, 2026 and Schedules May 25, 2026 Conference Call

    07
  8. May 21, 2026 · 17:00 · WOLF · Routine +

    Grey Wolf Health Corp.

    GREY WOLF ANIMAL HEALTH REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS

    08
  9. May 21, 2026 · 14:12 · NVRS · Material −

    Founder cashes out completely after boardroom shake‑up, casting a dark shadow over the sudden stem‑cell pivot.

    Noveris shareholder Bartch disposes of shares

    09
  10. May 21, 2026 · 09:00 · BPC · Routine +

    McGregor and Trump Jr. muscle into peptide marketing pact, but needle-free patch launch remains the real prize

    Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets

    10
  11. May 21, 2026 · 07:31 · BPC · Routine +

    Precision Peptide Solidifies MMA Partnership While Regulatory Clock Ticks Toward July Review

    The Precision Peptide Company (BPC) Expands on Exclusive 50/50 Revenue Share Peptide Partnership with MMA.INC (MMA)

    11
  12. May 21, 2026 · 07:30 · UDOC · Routine +

    UniDoc Revenue Milestone Masks Cash Burn Risks Amidst Downtrend

    UniDoc Reflects on Successes One Year After AMD Telemedicine Software Purchase

    12
  13. May 21, 2026 · 07:15 · ALGO · Material −

    Light AI’s C$5 Million Lifeline Comes With Dilutive Terms and Board Strings as Cash Burn Intensifies

    Light AI Announces C$5,000,000 Secured Convertible Debenture Unit Financing

    13
  14. May 21, 2026 · 07:00 · COV · Material +

    Covalon doubles down on infection prevention as CovaClear U.S. sales soar sixfold; zero-debt balance sheet and surging margins fuel re-rating.

    Covalon Reports 2026 Second Quarter Results

    14
← Newer Older →